Logo

Caliway Reports the IND Acceptance of CBL-514 by the US FDA for the Treatment of Dercum's Disease

Share this
Caliway

Caliway Reports the IND Acceptance of CBL-514 by the US FDA for the Treatment of Dercum's Disease

Shots:

  • The US FDA has accepted the IND application of the company’s CBL-514 to conduct a P-II (CBL-0202DD) trial for the treatment of Dercum's Disease
  • The P-II (CBL-0202DD) trial will investigate the efficacy, safety, and tolerance of CBL-514 vs PBO for treating Dercum's disease. Patient enrolment will begin in Q2’24
  • The previous P-II (CBL-0201DD) study evaluating CBL-514 has shown its efficacy in reducing lipoma dimension by >50% and significantly improving pain by 4.7 points, indicating the potential to become the first approved treatment for Dercum's disease

Ref: Caliway | Image: Caliway 

Related News:- Senti Bio Receives the US FDA’s Clearance on IND Application Submitted for SENTI-202 to Treat Hematologic Malignancies

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions